Plk1 a potential target for cancer therapy
Webb1 apr. 2006 · PLK1 is overexpressed in human tumours and has prognostic potential in cancer, indicating its involvement in carcinogenesis and its potential as a therapeutic …
Plk1 a potential target for cancer therapy
Did you know?
Webb9 apr. 2024 · Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy Download PDF. Your ... aiming to evaluate PLK1 as a potential target for the treatment of cancer 14,15,16,17. Webb23 juli 2024 · Several PLK1 inhibitors have been tested in phase I or II clinical studies in patients with various cancers, we used BI2536, which has been reported to be a potent …
Webb16 mars 2024 · RNA interference (RNAi), also known as gene silencing, is a biological process that prevents gene expression in certain diseases such as cancer. It can be used to improve the accuracy, efficiency, and stability of treatments, particularly genetic therapies. However, challenges such as delivery of oligonucleotide drug to less … Webb24 nov. 2016 · Polo-like kinase 1 (PLK1) plays an important role in the initiation, maintenance, and completion of mitosis. Dysfunction of PLK1may promote cancerous …
Webb13 apr. 2024 · Understanding the mechanism of action of rigosertib has potential clinical implications worth exploring, as it may help to tailor cancer therapies and improve patient outcomes. First , rigosertib was described as an inhibitor of the mitotic master regulator Polo-like kinase 1 (Plk1). WebbPLK4 plays an important role in centrosome amplification and tumor progression. PLK4 inhibitors used alone or in combination with other drugs have shown significant …
Webb14 okt. 2011 · This review describes inhibitors of a regulator of mitotic spindle formation, Polo-like kinase 1 (Plk1), introduces the rationale for targeting Plk1 in cancer therapy, and discusses preclinical and early clinical data from studies of Plk1 inhibitors, with a particular focus on non–small cell lung cancer (NSCLC).
Webb8 aug. 2024 · Human cancers driven by oncogenic KRAS mutations are common and among the most difficult-to-treat tumors. This study reports a synergistic drug combination by targeting FGFR1 and PLK1 and identifies autophagy as a protective mechanism that limits the efficacy of FGFR1/PLK1 inhibitor therapy in KRAS-mutant lung cancer, … kuvera add bank accountWebb15 jan. 2024 · 1. Introduction. PLK1 gene is a vital oncogene in preventing cancer cells from apoptosis and regulating cancer cell invasiveness [1], [2], [3].The overexpression of PLK1 protein is often found clinically correlated with poor prognosis, advanced disease stage, metastasis, drug-resistance and short survival [4], [5], [6].The past years has seen … kuvempu in kannadaWebbPlk1 gene and protein expression has been proposed as a new prognostic marker for many types of malignancies, and Plk1 is a potential target for cancer therapy. In this review, … kuvera companyWebb1 aug. 2004 · Otherwise, Polo-like kinase 1 (PLK1) plays a key role in mitotic progression and cell-cycle control [37], which is confirmed to be one of the potential drug targets for … kuvera memberWebb1 okt. 2015 · As survivin has been implicated in chemoresistance in cancer, it is regarded as a promising target for cancer therapy (55). Survivin is targeted by several strategies such as small molecule ... jayne ripleyWebb23 mars 2024 · The aim of this study is to assess potential correlations between PLK1 expression and ... High- and low-risk BRCA patients identified by the risk model responded differently to anti-PD-1 and/or anti-CTLA4 therapy, as well as common ... 17 Therefore, PLK1 is a critical target for cancer treatment. 18 PLK1 also controls the ... jayne siau jamie goh \u0026 lokeWebb9 apr. 2024 · PLK1 represents a model protein kinase target for cancer drug development because in addition to its kinase domain, which is related to members of the superfamily … jayne rivera 20